glp-1 and gallbladder disease Medications: What You Need to Know About Side Effects — Prodigy Care Services GLP-1 and Increased Incidence of

There is some indirect evidence to suggest that excess lysine in the diet may increase endogenous L-carnitine synthesis

Summary of CV and Renal Outcomes with SGLT2i and DPP4i Agents SGLT2: Inhibitor Cardiovascular Outcome Trials Cardiovascular outcome trials (CVOTs) have consistently shown that treatment with SGLT2i reduces hospitalization for heart failure (HHF) and secondary renal outcomes in terms of incident or worsening nephropathy in patients with T2DM and CV disease

L.LiL.et al

Employers managing rising drug costs can see those impacts to their bottom line

Focus on adequate protein intake, which becomes critical during rapid weight loss to preserve lean muscle mass